Bloocell® is the world’s first Artificial Tissue Technology, developed within the field of tissue engineering for the treatment of tissue deficiencies. It can be produced in complementary, therapeutic, and patient-specific anatomical forms, representing a breakthrough innovation in regenerative medicine.
With its proprietary technology, Bloocell® has become the first legally recognized representative of this paradigm worldwide, achieving successful clinical outcomes in multiple medical applications.

Bloocell® is a three-dimensional bioscaffold designed for the treatment of damaged or missing tissues. It supports cell growth, tissue formation, and the overall healing process, offering a comprehensive therapeutic solution. While providing structural support to the affected area, Bloocell® also facilitates cell proliferation and differentiation within an optimal biological environment.

Manufactured from biocompatible materials, Bloocell® integrates safely into the body without triggering immune rejection. Being biodegradable, it is gradually absorbed by the body, leaving behind regenerated tissue — enabling the natural formation and restoration of healthy tissue during the healing process.

Bloocell® enables the reconstruction of multiple tissue types, including bone, cartilage, skin, nerve, liver, and kidney, offering a broader range of applications and lower complication risks compared to conventional grafts.

In 2022, the global graft market reached USD 4.76 billion, while the next-generation biomaterials market followed with USD 1.76 billion — both growing at a compound annual rate of 13.87%. Meanwhile, the tissue engineering market has expanded to approximately USD 35 billion, continuing to grow significantly each year. Within this rapidly advancing landscape, Bloocell® is continuously evolving to become a global industry leader in artificial tissue technologies.

Bloocell® technology was developed as a result of extensive laboratory and preclinical studies conducted by Turkish scientists in the United States, and was successfully industrialized, patented, and clinically validated through the efforts of Turkish engineers and entrepreneurs. Having obtained all necessary regulatory approvals, Bloocell® has been transformed into a certified medical product and introduced to the market.

With the valuable support of distinguished professors from Boğaziçi University’s Life Sciences Department, a full-scale production line was established, enabling the transition from research to commercialization.

Through rigorous laboratory and preclinical research, the effects of Bloocell® on cells — including biocompatibility, mechanical strength, mineralization rate, and angiogenic potential — have been comprehensively studied. The results of these analyses and product validations have proven highly successful.

In the short term, Bloocell® aims to:
Complete FDA approval procedures for its U.S.-based entity, Bloocell® Technology Inc.,
Introduce its products to the U.S. and Canadian markets,
Finalize a distribution agreement in Brazil,
Obtain ANVISA approval to enter the South American market,
Establish Bloocell® Europe headquarters, and
Secure permissions for multi-center clinical studies in Türkiye.

In the medium term, the company plans to expand into the Chinese, Indian, Russian, and African markets, complete the construction of a new production facility, and secure investment from major international venture and crowd funds during its second investment round.

In the long term, Bloocell®’s vision is to develop innovative solutions for organ transplantation and large-scale tissue loss, improving patient outcomes worldwide while reaching a company valuation of 1 billion USD.

In 2023, Bloocell® successfully raised ₺21,230,426 with a 151.6% funding rate through Fonbulucu, Türkiye’s largest investment crowdfunding platform. The company has since expanded its team with experienced industry executives and R&D specialists. To ensure patient safety, all Bloocell® products are protected under international insurance policies. Furthermore, a stem cell integration project, designed to treat extensive tissue losses, has been launched with KOSGEB support.

Bloocell® continues to strengthen its presence in the European market. During its Italian distribution meetings and market visits, the products attracted significant interest from medical professionals and institutions. The company’s clinical research and commercial expansion activities are actively ongoing.

Bloocell®’s successful clinical outcomes were recently published at one of the world’s leading scientific congresses, jointly organized by the European Association for Osseointegration (EAO) and the German Society of Implantology (DGI):

“3-Dimensional Evaluation of E-Polycaprolactone Containing Membrane’s Efficacy in Guided Bone Regeneration: A Retrospective Study.”

At Bloocell®, our driving force is the belief that every scientific breakthrough can transform a life. We are motivated by a deep commitment to advancing healthcare through innovation, precision, and compassion. We dedicate our work to developing technologies that not only heal tissues but also restore hope, confidence, and quality of life for patients around the world. Each milestone we achieve is guided by the same purpose — to empower physicians with trusted solutions and to give patients the opportunity to recover naturally and fully. For us, motivation is not just about progress; it’s about shaping the future of medicine, one regenerated tissue at a time.

At Bloocell®, our vision is to redefine the boundaries of regenerative medicine and make advanced healing accessible to all. We are dedicated to improving the quality of human life by developing innovative, safe, and personalized artificial tissue technologies that empower both physicians and patients. We envision a future where tissue loss, organ failure, and complex reconstructive challenges are no longer barriers to living a full and healthy life. Through continuous scientific research, global collaboration, and a patient-centered approach, Bloocell® aims to lead the world in creating a new standard of care — where science and humanity heal together.